Re-irradiation in the thorax - An analysis of efficacy and safety based on accumulated EQD2 doses.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
11 2020
Historique:
received: 26 03 2020
revised: 13 07 2020
accepted: 20 07 2020
pubmed: 28 7 2020
medline: 15 4 2021
entrez: 28 7 2020
Statut: ppublish

Résumé

Thoracic re-irradiation remains a challenge regarding the balance of local efficacy and acceptable toxicities. In this retrospective analysis we analyzed dosimetrical and clinical data of patients treated with thoracic re-irradiation based on accumulated EQD2Gy doses. We retrospectively analyzed the data of 42 consecutive single-institutional patients treated with repeated courses of thoracic radiotherapy from 12/2011 to 01/2017. Accumulated EQD2 dose distributions were calculated and dose parameters for organs at risk and target volumes were analysed. The median prescription dose was 42.2 Gy (10-70.6 Gy) for all RT courses. The median Dmean of both lungs was 10.1 Gy Even though several organs at risk received maximum accumulated doses of >100 Gy

Identifiants

pubmed: 32717358
pii: S0167-8140(20)30678-2
doi: 10.1016/j.radonc.2020.07.033
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-62

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

C Schröder (C)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Canter for Proton Therapy, Paul Scherrer-Institut, Villigen, Switzerland.

I Stiefel (I)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

S Tanadini-Lang (S)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

I Pytko (I)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

E Vu (E)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

M Guckenberger (M)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

N Andratschke (N)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: nicolaus.andratschke@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH